Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CEA CAR T Cells in CEA Positive Cancer
NCT02349724Phase 1Unknown
- Sponsor
- Southwest Health System
- Start
- Dec 2014
- Primary completion
- Dec 2018
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-CEA CAR T cells in lung cancer, colorectal cancer (CRC), gastric cancer (GC) and 2 more (5 arms), sponsored by Southwest Health System. Primary endpoint: Adverse events of each patient at 3 years. Status: unknown.
02
Drugs
anti-CEA CAR T cells
03
Conditions
lung cancercolorectal cancer (CRC)gastric cancer (GC)breast cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02349724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02349724.